Abstract
Plasmodium falciparum parasites resistant to the combination sulfadoxine-pyrimethamine are spreading in Africa, particularly in East Africa. This is a matter of concern because there are no other affordable drugs available. This article provides the evidence indicating that sulfadoxine-pyrimethamine resistance can be reversed in vitro and discusses how this information might be exploited to extend the therapeutic lifetime of sulfadoxine-pyrimethamine in vivo.
| Original language | English |
|---|---|
| Pages (from-to) | 109-112 |
| Number of pages | 4 |
| Journal | Trends in Parasitology |
| Volume | 20 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2004 |
| Externally published | Yes |
Bibliographical note
Funding Information:We thank the director of Kenya Medical Research Institute for permission to publish these data. This work was supported by the Wellcome Trust (no. 056769). A.N. and K.M. are grateful to the Wellcome Trust for personal support. P.W. and S.A.W. are grateful to the Wellcome Trust for institutional support.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
ASJC Scopus subject areas
- Parasitology
- Infectious Diseases
Fingerprint
Dive into the research topics of 'Therapeutic potential of folate uptake inhibition in Plasmodium falciparum'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver